source
- Administration releases detailed report on most-favored-nation drug pricing, projects $529 billion savingsThe White House Council of Economic Advisers released its most detailed analysis yet of the administration's most-favored-nation drug pricing policy. The report defines the MFN pricing approach, w…
- CellCentric secures $220 million Series D to advance oral multiple myeloma drug inobrodibCellCentric, a biotech focused on multiple myeloma, announced a $220 million Series D financing led by Venrock. The capital will fund ongoing Phase 2 trials and a planned Phase 3 study of its oral…